Keyword: Baxter International
With $225 million from TPG Capital and Vida Ventures and $10 million from its founders and board members, AskBio will ramp up clinical trials and manufacturing.
Baxter’s Altapore bone graft substitute was cleared as a supplement to autografts of a patient’s bone in posterolateral spinal fusion surgeries.
Baxter received FDA clearance for a formulation of its Actifuse synthetic bone graft, deliverable via a prepackaged syringe requiring no preparation.
A study of 100 physicians who received payments from device makers declared their conflict of interest in journal articles only 37% of the time.
Here's Friday's medtech news of note.
The takeover will bolster Fresenius’ at-home dialysis unit, positioning it to profit if patients opt against receiving treatment in its care centers.
Baxter launched a new type of hemodialysis in a handful of countries, which uses a new dialyzer that filters a greater range of molecules from the blood, better simulating the function of a natural kidney.
Baxter is teaming up with dialysis care provider Satellite Healthcare to make advanced care available to more patients in the U.S.
Robert Parkinson had a lot on his plate during his last year as Baxter’s CEO in 2015. The med tech helmsman oversaw a spinout of the company’s biopharma business, Baxalta, before former Covidien CEO Jose Almeida took the reins in 2016.
Sunshine Heart has acquired Baxter International’s line of Aquadex products. Per the agreement, Baxter will bring in $4 million in cash and 1 million shares of Sunshine’s common stock.